Now showing items 2-21 of 84

      Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus vaccine trials: restoration of previously unpublished methodology [1]
      Adverse Events After Vaccination [1]
      Another question for GSK [1]
      Antibiotics Approved for Marketing in Populations Specifically Excluded From Premarketing Trials, 1999-2018 [1]
      Are manufacturers sharing data as promised? [1]
      Are US flu death figures more PR than science? [1]
      Authors' reply to Dunning [1]
      Availability of study protocols for randomized trials published in high-impact medical journals: A cross-sectional analysis. [1]
      Calibrated response to emerging infections [1]
      Canada finally opens up data on new drugs and devices: Other regulators should take note of Health Canada’s substantive reforms [1]
      CDC tightens controls on scientists’ communication with news media [1]
      Challenges of independent assessment of potential harms of HPV vaccines [1]
      Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy [1]
      Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports [1]
      Clinical trial data: get them while you can [1]
      Contradictory findings on efficacy of neuraminidase inhibitors not cited [1]
      Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies [1]
      Convicting Zika [1]
      Correction: Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: A protocol [Syst Rev. 4, (2015) (143)] DOI: 10.1186/s13643-015-0134-z. [1]
      Covid-19 vaccine trial protocols released [1]